Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
暂无分享,去创建一个
H. van de Velde | D. Reece | Y. Elsayed | G. Merlini | U. Hegenbart | S. Dubrey | J. Bladé | C. Enny | G. Palladini | V. Sanchorawala | J. Fermand | R. Comenzo | A. Cakana | H. Hassoun | S. Mortimer | R. Vescio | L. Heffner | P. Ramaswami | X. Liu | H. V. D. van de Velde
[1] M. Dimopoulos,et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Reece,et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. , 2009, Blood.
[3] G. Merlini,et al. Current treatment of AL amyloidosis , 2009, Haematologica.
[4] S. Iskandar,et al. Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature , 2009, Current cardiology reviews.
[5] G. Merlini,et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide , 2009, Annals of Hematology.
[6] A. Dispenzieri,et al. Long Term Follow-up of Patients with Immunoglobulin Light Chain Amyloidosis Treated with Lenalidomide and Dexamethasone. , 2008 .
[7] P. Hawkins,et al. Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis , 2008 .
[8] R. Stam,et al. Specific Promoter CpG Island Methylation Patterns Identify Different Subgroups of MLL - Rearranged Infant Acute Lymphoblastic Leukemia, and Define Clinical Outcome , 2008 .
[9] M. Maurer,et al. Predictors of survival in patients with systemic light‐chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone , 2008, British journal of haematology.
[10] R. Mori,et al. Diagnosis of UTI: results of an evidence based approach to guideline development carried out for the National Institute for Health and Clinical Excellence (NICE) , 2008 .
[11] G. Palladini,et al. Amyloidosis: is a cure possible? , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] P. Hawkins,et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease , 2008, Haematologica.
[13] H. Goldschmidt,et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[14] Anthony Boral,et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. , 2007, Blood.
[15] M. Salvadori,et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] M. Dimopoulos,et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone , 2007, Haematologica.
[17] G. Merlini,et al. Bortezomib in the treatment of AL amyloidosis: targeted therapy? , 2007, Haematologica.
[18] H. Goldschmidt,et al. Non‐invasive predictors of survival in cardiac amyloidosis , 2007, European journal of heart failure.
[19] N. Munshi,et al. New drugs for myeloma. , 2007, The oncologist.
[20] R. Comenzo. Managing systemic light-chain amyloidosis. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[21] A. Dispenzieri,et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. , 2007, Blood.
[22] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[23] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[24] G. Merlini,et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). , 2005, Blood.
[25] J. Crowley,et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. , 2004, Blood.
[26] D. Esseltine,et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma , 2004, British journal of haematology.
[27] T. Therneau,et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. , 2004, Blood.
[28] T. Therneau,et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Paul J. Wang,et al. Electrocardiographic arrhythmia risk testing. , 2004, Current problems in cardiology.
[30] G. Merlini,et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. , 2004, Blood.
[31] R. Falk,et al. High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study , 2004, Annals of Internal Medicine.
[32] Giampaolo Merlini,et al. Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.
[33] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[34] R. Vij,et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] A. Balduini,et al. Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.
[36] G. Palladini,et al. Holter Monitoring in AL Amyloidosis: Prognostic Implications , 2001, Pacing and clinical electrophysiology : PACE.
[37] E. Ascari,et al. A modified high‐dose dexamethasone regimen for primary systemic (AL) amyloidosis , 2001, British journal of haematology.
[38] Stefan H. Thomke,et al. Millennium Pharmaceuticals, Inc. , 1999, Personalized medicine.
[39] T. Therneau,et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. , 1999, Blood.
[40] R. Falk,et al. Resolution of Heart Failure in Patients with AL Amyloidosis , 1996, Annals of Internal Medicine.
[41] A. Ballestrero,et al. Proteasome inhibitors: antitumor effects and beyond , 2007, Leukemia.
[42] M. Skinner,et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. , 2007, Blood.
[43] R. Comenzo. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. , 2007, Contributions to nephrology.
[44] It Istituto Superiore di Sanit,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 , 2005 .
[45] Guidelines on the diagnosis and management of AL amyloidosis. , 2004, British journal of haematology.
[46] A. Dispenzieri,et al. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report , 2000, Bone Marrow Transplantation.
[47] J. Buxbaum,et al. The systemic amyloidoses. , 1998, The New England journal of medicine.
[48] R. Kyle,et al. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.
[49] R. Falk,et al. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. , 1984, Journal of the American College of Cardiology.
[50] B Lown,et al. Management of patients with malignant ventricular arrhythmias. , 1977, The American journal of cardiology.